Why targeted therapies are necessary for systemic lupus erythematosus.

Item

http://www.wikidata.org/entity/Q38920435

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Why targeted therapies are necessary for systemic lupus erythematosus.

@en

type

Item

label

Why targeted therapies are necessary for systemic lupus erythematosus.

@en

prefLabel

Why targeted therapies are necessary for systemic lupus erythematosus.

@en

P1476

Why targeted therapies are necessary for systemic lupus erythematosus.

@en

P2093

L Durcan

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Hydroxychloroquine in lupus pregnancy.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

P304

1070-1079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203316652489

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michelle A. Petri

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27497251

http://www.w3.org/2001/XMLSchema#string

P932

4978144

http://www.w3.org/2001/XMLSchema#string